Ashurst advises on Hanx Biopharmaceuticals’ HK$586 million Hong Kong listing
23 December 2025
Global law firm Ashurst represented ICBC International Capital Limited, as the Hong Kong and U.S. legal advisers on Hanx Biopharmaceuticals (Wuhan) Co., Ltd.’s (SEHK: 3378) HK$586.3 million global offering and the listing of its H shares on the Main Board of The Stock Exchange of Hong Kong Limited.
Hanx Biopharmaceuticals is a China-based biopharmaceutical company primarily engaged on the research and development of innovative therapies, including biologics, with activities spanning discovery, clinical development, and manufacturing.
Commenting on the transaction, Frank Bi, partner and Asia head of corporate transactions, said:
“We are pleased to support the underwriters on Hanx Biopharmaceuticals’ Hong Kong IPO. This transaction highlights our deep experience in the biopharmaceuticals sector. Throughout this year, our integrated Hong Kong and U.S. team has advised on a number of significant IPOs across the region, including in life sciences, and we remain focused on delivering clear, sector-focused advice to both underwriters and issuers.”
The Ashurst team was led by Frank Bi , with support from partner Li Jiang, counsel Christy Li, Nicole Xu, Ferren Cee, Li Chen, Vicky Yeung, Hans Kang, Peiji Yu, Elena Guo, Judy Zhou, and Joanne Wong
